Unfractionated heparin during the interruption of antiplatelet therapy for non-cardiac surgery after drug-eluting stent implantation

Internal Medicine

Volumn 55, Issue 4, 2016, Pages 333-337

  Tanaka, Akihito ^a   Ishii, Hideki ^a   Tatami, Yosuke ^a   Shibata, Yohei ^a   Osugi, Naohiro ^a   Ota, Tomoyuki ^a   Kawamura, Yoshihiro ^a   Suzuki, Susumu ^a   Nagao, Yoshimasa ^b   Matsushita, Tadashi ^b   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Antiplatelet therapy; Drug eluting stent; Non cardiac surgery; Unfractionated heparin

Indexed keywords

ANTITHROMBOCYTIC AGENT; EVEROLIMUS; HEPARIN; PACLITAXEL; RAPAMYCIN; UMIROLIMUS; ZOTAROLIMUS;

AGED; ARTICLE; BLOOD CLOT LYSIS; CANCER SURGERY; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DRUG ELUTING STENT; FEMALE; HEART DISEASE; HEART INFARCTION; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; RETROSPECTIVE STUDY; CONTRAINDICATIONS; CORONARY THROMBOSIS; DRUG ADMINISTRATION; EPIDEMIOLOGY; JAPAN; PRACTICE GUIDELINE; PROCEDURES; THORAX SURGERY; TIME FACTOR; TREATMENT OUTCOME;

AGED; CORONARY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG-ELUTING STENTS; FEMALE; HEPARIN; HUMANS; JAPAN; MALE; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; THORACIC SURGICAL PROCEDURES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84958186038     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.55.5495     Document Type: Article

References (23)

1. Berger PB, Kleiman NS, Pencina MJ, et al. Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. JACC Cardiovasc Interv 3: 920-927, 2010.
2. Abualsaud AO, Eisenberg MJ. Perioperative management of patients with drug-eluting stents. JACC Cardiovasc Interv 3: 131-142, 2010.
3. Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115: 813-818, 2007.
4. Riddell JW, Chiche L, Plaud B, Hamon M. Coronary stents and noncardiac surgery. Circulation 116: e378-e382, 2007.
5. Tanaka A, Sakakibara M, Ishii H, et al. The risk of adverse cardiac events following minor surgery under discontinuation of all anti-platelet therapy in patients with prior drug-eluting stent implantation. Int J Cardiol 172: e125-e126, 2014.
6. Singla S, Sachdeva R, Uretsky BF. The risk of adverse cardiac and bleeding events following noncardiac surgery relative to antiplatelet therapy in patients with prior percutaneous coronary intervention. J Am Coll Cardiol 60: 2005-2016, 2012.
7. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: e326S-e350S, 2012.
8. Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol 54: e13-e118, 2009.
9. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guide- lines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35: 2541-2619, 2014.
10. Chassot PG, Delabays A, Spahn DR. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 99: 316-328, 2007.
11. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 115: 256-265, 1991.
12. Brilakis ES, Patel VG, Banerjee S. Medical management after coronary stent implantation: a review. JAMA 310: 189-198, 2013.
13. Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 30: 2769-2812, 2009.
14. Hawn MT, Graham LA, Richman JS, et al. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA 310: 1462-1472, 2013.
15. Tokushige A, Shiomi H, Morimoto T, et al. Incidence and out-come of surgical procedures after coronary bare-metal and drug-eluting stent implantation: a report from the CREDO-Kyoto PCI/ CABG registry cohort-2. Circ Cardiovasc Interv 5: 237-246, 2012.
16. Korte W, Cattaneo M, Chassot PG, et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (OGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 105: 743-749, 2011.
17. Alshawabkeh LI, Banerjee S, Brilakis ES. Systematic review of the frequency and outcomes of non-cardiac surgery after drug-eluting stent implantation. Hellenic J Cardiol 52: 141-148, 2011.
18. Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H. Coronary artery stenting and non-cardiac surgery: a prospective outcome study. Br J Anaesth 96: 686-693, 2006.
19. Dent H, Lekic Z, Vicenzi M. Unfractionated heparin and coronary artery stenting. Br J Anaesth 97: 582, 2006.
20. Anwaruddin S, Askari AT, Saudye H, et al. Characterization of post-operative risk associated with prior drug-eluting stent use. JACC Cardiovasc Interv 2: 542-549, 2009.
21. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 327: 141-145, 1992.
22. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97: 251-256, 1998.
23. Alshawabkeh LI, Prasad A, Lenkovsky F, et al. Outcomes of a preoperative ”bridging” strategy with glycoprotein IIb/IIIa inhibitors to prevent perioperative stent thrombosis in patients with drug-eluting stents who undergo surgery necessitating interruption of thienopyridine administration. EuroIntervention 9: 204-211, 2013.